We use cookies to keep our site safe and provide an enhanced, personalized experience. You can choose to accept or manage optional cookies. More details about how we protect and use your information can be found in our Privacy Policy.
Viruses and Multiple Sclerosis
Infectious Agents and Multiple Sclerosis
Epstein-Barr virus (EBV) is very common, and most people are exposed to it in childhood, generally with mild or no symptoms. In adolescence and adulthood, it can cause infectious mononucleosis, a disease that increases the risk of later developing MS. The virus stays inactive in the body throughout a person’s lifetime and has been linked to certain cancers and autoimmune diseases. EBV can be reactivated by a trigger.Several studies led by Alberto Ascherio, M.D., Dr.P.H., (Harvard School of Public Health) provide the strongest evidence yet in the role of EBV in triggering MS. They show that EBV infection precedes both the symptoms of MS and nervous system damage and that becoming infected significantly increases the risk of developing MS in people whose genetic background, environment and lifestyle also add to their risk of getting MS.The studies found that:
Antibodies (immune proteins that indicate a person has been exposed) to EBV were much higher in people who eventually developed MS than in control samples of people who did not get the disease.
MS risk increased significantly following infection with EBV, thereby demonstrating that EBV was in the body before MS developed.
People with a specific immune-related gene and high levels of antibodies to EBV in their blood were 9 times more likely to develop MS than those without the gene and with low levels of the antibodies.
Current or previous smokers with the highest levels of EBV antibodies were 70% more likely to develop MS than those with neither risk factor.Learn more about the link between MS and the Epstein-Barr virus:
Human herpes virus (HHV-6) may also be involved in MS — specifically by triggering relapses. A team in Spain found that HHV-6 antibodies reached their highest levels in people with MS two weeks before a relapse occurred. These researchers suggest that tracking HHV-6 antibodies may help to predict the clinical course of MS.